Pancreatic adenocarcinoma is a heterogeneous disease in which each patient present specific tumor characteristics that conditions the outcome of the disease. Most patients are treated accordingly to their general fitness status without taking into account their tumor characteristics. However, the evolution and the treatment response is associated with the tumor cell intrinsic characteristics (phenotype), which in turn, is determined by the overall gene expression. Our recent studies allowed the identification of “molecular signatures” based on gene expression that predicts the patient clinical outcome and the tumor response to the available treatments. These signatures open the doors to a personalized medicine of pancreatic adenocarcinoma. This new molecular approach we developed will greatly increase the effectiveness of treatments.Nelson Dusetti is an oncology researcher with expertise in pancreatic cancer. He developed an innovative approach for predicting tumor response to chemotherapy using transcriptomic signatures validated in clinical studies. As director of the Translational Research and Innovative Therapies department, he currently leads the Translational and Therapeutic Targets Research in Pancreatic Cancer team. Dusetti co-founded Predicting Med, a startup aiming to commercialize molecular tests for chemotherapy in PDAC.